Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Mirum Pharmaceuticals Inc Market Cap
Based on ratings from 11 stock analysts, the Mirum Pharmaceuticals Inc stock price is expected to increase by 35.32% in 12 months. This is calculated by using the average 12-month stock price forecast for Mirum Pharmaceuticals Inc. The lowest target is $50 and the highest is $73. Please note analyst price targets are not guaranteed and could be missed completely.
About 11 Wall Street analysts have assigned MIRM 11 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Mirum Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on MIRM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of MIRM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brian Skorney Baird | Outperform | $50 | Maintains | Nov 13, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $66 | Reiterates | Nov 13, 2024 |
| David Lebowitz Citigroup | Buy | $68 | Maintains | Nov 13, 2024 |
| Mani Foroohar Leerink Partners | Outperform | $49 | Maintains | Oct 17, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $66 | Reiterates | Oct 11, 2024 |
| Gavin Clark-Gartner Evercore ISI Group | Outperform | $66 | Maintains | Aug 8, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $60 | Maintains | Aug 8, 2024 |
| Brian Skorney Baird | Outperform | $44 | Maintains | Aug 8, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $66 | Reiterates | Jul 26, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $66 | Reiterates | Jul 8, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $66 | Reiterates | Jun 28, 2024 |
| Dae Gon Ha Stifel | Buy | $66 | Maintains | Jun 20, 2024 |
| Michael Ulz Morgan Stanley | Overweight | $57 | Maintains | Jun 18, 2024 |
| David Lebowitz Citigroup | Buy | $64 | Maintains | Jun 18, 2024 |
| Jessica Fye JP Morgan | Overweight | $39 | Maintains | Jun 18, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $68 | Maintains | Jun 18, 2024 |
| Brian Skorney Baird | Outperform | $39 | Maintains | Jun 17, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $66 | Maintains | Jun 17, 2024 |
| Dae Gon Ha Stifel | Buy | $48 | Reiterates | Jun 17, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $58 | Reiterates | Jun 7, 2024 |
When did it IPO
2019
Staff Count
311
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Christopher Peetz
Market Cap
$2.24B
In 2023, MIRM generated $186.4M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MIRM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Mirum Pharmaceuticals will present data on its LIVMARLI and Volixibat clinical programs at AASLD's The Liver Meeting, indicating ongoing research and development efforts.
Why It Matters - Mirum Pharmaceuticals' presentation at a key medical conference highlights its clinical advancements, potentially influencing stock performance and investor sentiment in the biotech sector.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Mirum Pharmaceuticals will hold its Q3 2024 Earnings Conference Call on November 12, 2024, at 8:30 AM ET, featuring key executives and analysts from major firms.
Why It Matters - The Q3 2024 earnings call will provide insights into Mirum Pharmaceuticals' financial performance and future strategies, influencing investor sentiment and stock valuation.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Mirum Pharmaceuticals has reported its financial results for Q3 2024 and provided a business update. Further details on performance and projections are available in the report.
Why It Matters - Mirum Pharmaceuticals' Q3 2024 results and business update can indicate financial health, growth potential, and future profitability, influencing investment decisions and stock performance.
Tue, 12 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - MIRM's Q3 2024 earnings and revenues exceeded estimates, prompting the company to raise its revenue guidance for 2024.
Why It Matters - MIRM's strong Q3 performance and raised revenue guidance indicate robust growth potential, positively impacting investor confidence and stock valuation.
Tue, 12 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Mirum Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the estimated loss of $0.45, and an improvement from a loss of $0.57 per share a year earlier.
Why It Matters - Mirum Pharmaceuticals' smaller-than-expected loss signals improved financial performance, potentially boosting investor confidence and impacting stock price positively.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Mirum Pharmaceuticals announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
Why It Matters - Mirum Pharmaceuticals' inducement grants may signal potential growth or strategic shifts, affecting investor sentiment and stock performance in response to future developments.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
